In patients with severe CAC, IL-37 levels were significantly elevated, representing a potential future biomarker for severe CAC.[153] In diabetic mice, IL-37 treatment attenuated vascular calcification and atherosclerosis progression with its effects partially mediated by osteoprotegerin.[159] These findings suggest IL-37 nomination as a therapeutic target for preventing or treating atherosclerotic diseases and vascular calcification. The gene discussed is IL37; the disease is atherosclerosis.